GB2223496A - Gene encoding human acidic fibroblast growth factor - Google Patents
Gene encoding human acidic fibroblast growth factor Download PDFInfo
- Publication number
- GB2223496A GB2223496A GB8818775A GB8818775A GB2223496A GB 2223496 A GB2223496 A GB 2223496A GB 8818775 A GB8818775 A GB 8818775A GB 8818775 A GB8818775 A GB 8818775A GB 2223496 A GB2223496 A GB 2223496A
- Authority
- GB
- United Kingdom
- Prior art keywords
- gga
- gaa
- dna
- construct
- caa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 13
- 101000846416 Homo sapiens Fibroblast growth factor 1 Proteins 0.000 title abstract description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 11
- 239000013612 plasmid Substances 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims description 4
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 claims description 2
- 101100364971 Mus musculus Scai gene Proteins 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 244000062730 Melissa officinalis Species 0.000 claims 1
- 235000010654 Melissa officinalis Nutrition 0.000 claims 1
- 239000000865 liniment Substances 0.000 claims 1
- 238000010348 incorporation Methods 0.000 abstract description 4
- 238000012219 cassette mutagenesis Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 25
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 17
- 239000000499 gel Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 210000002889 endothelial cell Anatomy 0.000 description 6
- 108700005078 Synthetic Genes Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical class NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004160 Ammonium persulphate Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010086093 Mung Bean Nuclease Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 1
- 235000019395 ammonium persulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000001736 capillary Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 108700004203 eye-derived growth factor Proteins 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 101150085823 hsdR gene Proteins 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Synthetic DNA coding for human acidic fibroblast growth factor includes the following sequence: <IMAGE> and incorporates useful restriction sites at frequent intervals to facilitate the cassette mutagenesis of selected regions. Also included are flanking restriction sites to simplify the incorporation of the gene into any desired expression system.
Description
SYNTHETIC GENE
This invention relates to synthetic genes coding for mature Human Acidic Fibroblast Growth Factor (aFGF).
Acidic Fibroblast Growth Factor is a member of a group of anionic endothelial cell molecules including a and 6 Endothelial Cell Growth Factors, Eye Derived Growth
Factor and a-retina-derived Growth Factor. The role of these molecules in the regulation of endothelial cell activity is as yet only partly understood. It is suggested that along with a cationic group of proteins exemplified by basic Fibroblast Growth Factor the anionic molecules act in a 'cascade' effect to control endothelial cell activity either co-ordinately through synergistic effects or via independent routes.
The regulation of endothelial cells is essential to the protection of arteries, veins and capillaries from the effect of thrombogenesis. Endothelial cells do not show cell division except in the case of wounding of blood vessels, their stimulation and control by these factors is also thought to be important in the development of tumours and the process of atherosclerosis.
Human acidic Fibroblast Growth Factor has been isolated and purified its amino acid sequence is reported in the literature. Based on comparisons with the bovine molecule of the same type a relationship with
Endothelial Cell Growth Factor in each case has also been suggested. It is reported that processing of
Endothelial Cell Growth Factor through the cleavage of the first 15 amino acids generates aFGF in each case.
Since there may be specific biological activities associated with each particular molecule it is sought in this application to provide a unique DNA sequence encoding aFGF to allow expression of the molecule and analysis of its function in relation to its precursor.
In the assembly strategy of aFGF advantage is taken of the relationship with its precursor 6 Endothelial Cell
Growth Factor to permit modification and subcloning of a unique sequence by means of specifically synthesised oligonucleotides to provide and in frame 5' amino acid sequence.
In order to facilitate the dissection of the structure and function relationships of aFGF, its incorporation into expression vectors and the production of novel chimeric proteins containing aFGF functionality an improved novel synthetic gene for human aFGF is sought.
It is by no means easy to predict the design of an improved aFGF gene, since the factors that determine the expressibility of a given DNA sequence are still poorly understood. Furthermore, the utility of the gene in various applications will be influenced by such considerations as codon usage and restriction sites.
The present invention relates to a synthetic aFGF gene which is distinct from other published sequences of aFGF genes and has advantages in the ease with which it can be modified due to the prescence of useful restriction sites.
When synthesising and assembling genes, problems have been encountered when there are inverted or direct repeats greater than eight bases long in the DNA sequence. In addition, areas of unbalenced base composition such as G/C or A/T rich regions or polypurine/polypyrimidine tracts have been found to lead to inefficient expression. The present invention seeks to overcome or at least alleviate these difficulties.
According to a first aspect of the invention, -there is provided DNA coding for aFGF and having restriction sites for the following enzymes:
HinDIII, BspMI, AvaI, PstI, BspMII, PvuII, ScaI, SphI, Ural, BamHI and EcoRI.
According to a second aspect of the invention, there is provided DNA including the following sequence:
AAG CTT ACC TGC CAT GTT TAA TCT GCC TCC CGG GAA TTA CAA
GAA GCC CAA ACT CCT CTA CTG CAG CAA CGG GGG CCA CTT CCT
GAG GAT TCT TCC GGA TGG CAC AGT GGA TGG GAC AAG GGA CAG
GAG CGA CCA GCA CAT TCA GCT GCA ACT CAG TGC GGA AAG CGT
GGG GGA GGT GTA TAT AAA GAG TAC CGA GAC TGG CCA GTA CTT
GGC AAT GGA CAC CGA CGG GCT TTT ATA CGG CTC ACA GAC ACC
AAA TGA GGA ATG TTT GTT CCT GGA AAG GCT GGA GGA GAA CCA
TTA CAA CAC CTA TAT ATC CAA GAA GCA TGC AGA GAA GAA TTG
GTT TGT TGG CCT CAA GAA GAA TGG GAG CTG CAA ACG CGG TCC
TCG GAC TCA CTA TGG CCA GAA AGC AAT CTT GTT TCT CCC CCT
GCC AGT CTC TTC TGA TTA ATA AGG ATC CGA ATT C
A synthetic aFGF gene as described above incorporates useful restriction sites at frequent intervals to facilitate the cassette mutagenesis of selected regions.
Also included are flanking sites to simplify the incorporation of the gene into any desired expression system.
A further feature of the design is the inclusion of a
BspMI site just upstream of the initiator ATG. This enzyme is useful because it recognizes a non-palindromic sequence of six base pairs (S'-ACCTGC-3') and gives rise to a staggered cut in the DNA four bases downstream of the recognition site resulting in a four base cohesive end with a 5' extension. A suitable juxtaposition of the BspMI site and initiator ATG therefore allows for the generation of a blunt end immediately following the
ATG by the simple expedient of BspMI cleavage followed by repair of the cohesive end with DNA polymerase Klenow fragment as illustrated in figure 2. This approach is superior to other methods of fusing genes without the initiator methionine codon since it is completely indepedent of the nature of the coding sequence.For example, the enzyme NcoI that has the- recognition sequence CCATGG has been used in an analogous fashion since a gene can be engineered so that the initiator ATG is included in an NcoI site. Cleavage with NcoI followed by S1 or Mung Bean nuclease treatment will result in a blunt end following the ATG. This approach can only be used, however, when the codon following the
ATG commneces with a G residue. In addition, the nuclease treatment required is less reliable than the polymerase step needed for the BspMI approach.The use of BspMI sites in this way will greatly facilitate the incorporation of any synthetic or suitably modified gene into other expression sytems, in particular its fusion to a variety of secretion signals and to vectors designed for the expression of fusion proteins which include the recognition site for a specific protease such as factor X.
Synthetic genes in accordance with the invention are generally designed primarily for expression in higher eukaryotic systems, particularly mammalian cells but they are expected to be capable of expression in other systems including E.coli , yeast and insect cells.
According to a third aspect of the invention, there is provided a genetic construct comprising DNA according to the first or second aspect or a fragment thereof.
The fragment may comprise at least 10, 20, 30, 40, or 50 nucleotides. A genetic construct in accordance with the third aspest may be a vector, such as a plasmid, cosmid or phage.
According to a fourth aspect of the invention, there is provided a process for the preparation of DNA in accordance with the first or second aspect or a genetic construct in accordance with the third aspect, the process comprising coupling successive nucleotides and/or ligating appropriate oligomers.
The invention also relates to other nucleic acid (including RNA) either corresponding to or complementary to DNA in accordance with the first or second aspects.
Preferred embodiments and examples of the invention will now be described. In the following description reference is made to a number of drawings in which:
Figure 1 shows a cDNA sequence for aFGF together with deduced amino acid sequence;
Figure 2 illustrates the utility of having a BspMI site preceding the gene;
Figure 3 shows the sequence of an aFGF synthetic gene in accordance with the invention along with the location of useful restriction sites;
Figure 4 shows the sequence of an aFGF gene divided into oligonucleotides; and
Figure 5 shows a summary of an exemplary assembly procedure.
EXAMPLE
CONSTRUCTION OF THE GENE
The desired gene sequence was divided into 24 oligodeoxribonucleotides (oligomers) as depicted in Figure 4.
The division was such as to provide seven base cohesive ends after annealing complementary pairs of oligiomers.
The end points of the oligomers were chosen to minimise the potential for inappropriate ligation of oligomers at the assembly stage.
The oligomers were synthesised by automated solid phase phosphoramidite chemistry. Following de-blocking and removal from the controlled pore glass support the oligomers were purified on denaturing polyacrylamide gels, further purified by ethanol precipitation and finally dissolved in water prior to estimation of their concentration.
All the oligomers with the exception of the 5' terminal oligimers BB768 and BB791 were then kinased to provide them with a 5' phosphate as required for the ligation step. Complementary oligomers were then annealed and the pairs of oligomers ligated together by T4 DNA ligase as depicted in Figure 5. The ligation products were separated on a 2% low gelling temperature (LGT) gel and the band corresponding to the precursor aFGF 495/495 duplex was cut out and extracted from the gel.
The purified fragment was ligated to HinDIII/EcoRI cut
DNA of the plasmid put18. The ligated product was transformed into How87 and plated on L-agar plates containing 100mcg ml ampicillin. Colonies containing potential clones were then growl up in L-broth containing ampicillin at 100mcg ml and plasmid DNA isolated. Positive clones were identified by direct di-deoxy sequence analysis of the plasmid DNA using the 17 base universal primer and reverse sequencing primer complementary to pUC18 on each side of the polylinker region. To determine the sequence of certain internal regions oligomers used in the construction were also employed as sequencing primers.One clone of precursor aFGF was subsequently re-sequenced on both strands to confirm that no mutations were present.
Following the identification of this correct clone plasmid DNA was isolated and the DNA digested using
HinDIII and XmaI. The larger fragment containing the original plasmid sequence together with the majority of the cloned insert was isolated using LT agarose as described previously. A linker composed of the annealed oligonucleotides BB829 & BB830 providing HinDIII and
XmaI ends encompassing the correct 5'amino acid sequence was inserted as descibed above.
The isolation of a clone encoding the correct sequence for mature aFGF was performed in the manner descibed earlier following the methods described for transformation and plasmid sequencing.
METHODS
All the techniques of genetic manipulation used in the manufacture of this gene are well known to those skilled in the art of genetic engineering. A description of most of the techniques can be found in one of the following laboratory manuals: Molecular Cloning by T.Maniatis,E.F.
Fritsch and J. Sambrook published by Cold Spring Harbor
Laboratory, Box 100, New York USA, or Basic Methods in
Molecular Biolo by L.G. Davis, M.D. Dibner and J.F.
Battey published by Elsevier Science Publishing Co. Inc.
New York, USA.
Additional and modified methodologies are detailed below.
1) Oligonucleotide synthesis
The oligonucleotides were synthesised by automated phosphoramidite chemistry using cyanoethyl phosphoramidites. The methodology is now widely used and has been described (Beaucage, S.L and Caruthers,
M.H. Tetrahedron Letters. 24, 245 (1981)).
2) Purification of Oligonucleotides
The oligonucleotides were deprotected and removed from the CPG support by incubation in concentrated NH3.
Typically, 50mg of CPG carrying 1 micromole of oligogucleotide was deprotected by incubation for Shrs at 70 C in 600 mcl of concentrated NH3. The supernatant was transfered to a fresh tube and the oligomer precipitated with 3 volumes of ethanol. Following centrifugation the pellet was dried and resuspended in 1 ml of water. The concentration of crude oligomer was then determined by measuring the absorbance at 260 nm.
For gel purification 10 absorbance units of the oligonucleotide were dried down and resuspended in 15 mcl of marker dye (90% de-ionised formamide, 1OmM Tris, l0mM borate, lmM EDTA, 0.1% bOomophenol blue).
The samples were heated at 90 C for lmin and then loaded onto a 1.2mm thick denaturing polyacrylamide gel with 1.6mm wide slots. The gel was prepared from a stock of 15% acrylamide, 0.6% bisacrylamide and 7M urea in 1 X TBE and was polymerised with 0.1% ammonium persulphate and 0.025% TEMED. The gel was pre-run for 1 hr. The samples were run at 1500 volts for 4-5 hrs.
The bands were visualised by UV shadowing and those corresponding to the full length product were cut out and transfered to micro-testubes. The oligomers were were eluted from the gel slice in AGEB (0.5 M ammonium acetate, 0.01 M magnesium acetate and 0.1% SDS) overnight. The AGEB buffer was then transfered to fresh tubes and the oligomer precipitated with three volumes of ethanol at -70 C for 15min. The precipitate was collected by centrifugation in an Eppendorf microfuge for 10mint the pellet washed in 80% ethanol, the purified oligomer dried , redissolved im lml of water and finally filtered through a 0.45 micron micro-filter.
The concentration of purified product was measured by determining its absorbance at 260 nm.
3) Kinasing of oligomers 250 pmole of oligomer was dried down and resuspended in 20 mcl kinase buffer (70mM Tris pH 7.6, 10mM MgCl2, lmM
ATP, 0.2 mM spermidine, 0.5mM dithiothreitol). 10 units of T4 polynuclegtide kinase was added and the mixture incubated at 37 C for 30 min. The kinase was then inactivated by heating at 85 C for 15 min.
4) Annealing 8 mOcl of each pair of oligomer was mixed, heated to 90 C and then slow cooled to room temperature over a period of 1 hr.
5) Ligation 5 mcl of each annealed pair of oligomers were mixed and 10 X ligase buffer added to give a final ligase reaction mixture (50mM Tris pH 7.5, 10mM MgCl , 20mM dithiothreitol, lmM ATP). T4 DNA ligase was aided at a rate of 100 units per 50 mcl reaction and ligation was carried out at 15 C for 4 hr.
6) Agarose gel electrophoresis
Ligation products were separated using 2% low gelling temperature agarose gels in 1 X TBE buffer (0.094 M
Tris pH 8.3 0.089 M boric acid, 0.25mM EDTA) containing 0.5 mcg ml 1 ethidium bromide.
7)Isolation of the ligation product.
The band corresponding to the expected aFGF ligation product was identified by reference to size markers under long wave UV illumination. The band was cut out of the gel and the DNA extracted as follows.
The volume of the gel was estimated from its weight and then melted by incubation at 65 C for 10mien. The volume of the slice was then made up to 400 mcl with TE (l0mM Tris pH 8.0, lmM EDTA) and Na acetate added to a final concentration of 0.3 M. 10 mcg of yeast tRNA was also added as carrier. The DNA was the subjected to three rounds of extraction with equal volumes of TE equilibrated phenol followed by three extractions with water saturated ether. The DNA was precipitated with two volumes of ethanol, centrifuged for 10mien in a microfuge, the pellet washed in 70% ethanol and finally dried down. The DNA pellet was taken up in 20 mcl of TE and 2 mcl of this volume were run on a 2% agarose gel to estimate the recovery of DNA.
8) Cloning of fragment 0.5 mcg of pUC18 DNA was prepared by cleavage with
HinDIII and EcoRI as advised by the suppliers. The digested DNA was run on an 0.8% LGT gel and the vector band purified as described above.
20 ng of cut vector DNA was then ligated to various quantities of aFGF DNA ranging from 2 to 24 ng for 4 hr using the ligation buffer described above.
20ng of cut vector DNA was then ligated to various quantities of aFGF DNA ranging from 2 to 20 ng for 4 hr using the ligation buffer described above. The ligation products were used to transform competent HOWS7 as has been described. Ampicillin resistant transformants were selected on L-agar plates containing 100 mcg ml ampicillin.
9) Isolation of plasmid DNA
Plasmid DNA was prepared from the colonies containing potential aFGF clones essentially as described (Ish
Horowicz, D., Burke, J.F. Nucleic Acids Research 9 2989-2998 (1981).).
10) Dideoxy sequencing
The protocol used was essentially as has been described (Biggin, M.D., Gibson, T.J., Hong, G.F. P.N.A.S. 80 3963-3965 (1983)). The method was modified to allow sequencing on plasmid DNA as described (Guo, L.H., Wu,
R. Nucleic Acids Research 11 5521-5540 (1983).
11) Transformation
Transformation was accomplished using standard procedures. The strain used as recipient in the cloning was HW87 which has the following genotype: araD139(ara-leu)del7697 (lacIPOZY)del74 galU galK hsdR rpsL srl recATW Any other standard cloning recipient such as HB101 would be adequate.
Claims (11)
1. DNA coding for aFGF and having restriction sites for the following enzymes:
HinDIII, BspMI, AvaI, PstI, BspMII, PvuII, ScaI, SphI, Balm, BamHI and EcoRI.
2. DNA including the following sequence:
AAG CTT ACC TGC CAT GTT TAA TCT GCC TCC CGG GAA TTA CAA
GAA GCC CAA ACT CCT CTA CTG CAG CAA CGG GGG CCA CTT CCT
GAG GAT TCT TCC GGA TGG CAC AGT GGA TGG GAC AAG GGA CAG
GAG CGA CCA GCA CAT TCA GCT GCA ACT CAG TGC GGA AAG CGT
GGG GGA GGT GTA TAT AAA GAG TAC CGA GAC TGG CCA GTA CTT
GGC AAT GGA CAC CGA CGG GCT TTT ATA CGG CTC ACA GAC ACC
AAA TGA GGA ATG TTT GTT CCT GGA AAG GCT GGA GGA GAA CCA
TTA CAA CAC CTA TAT ATC CAA GAA GCA TGC AGA GAA GAA TTG
GTT TGT TGG CCT CAA GAA GAA TGG GAG CTG CAA ACG CGG TCC
TCG GAC TCA CTA TGG CCA GAA AGC AAT CTT GTT TCT CCC CCT
GCC AGT CTC TTC TGA TTA ATA AGG ATC CGA ATT C
3. A genetic construct comprising DNA as claimed in claim 1 or 2, or a fragment thereof.
4. A construct as claimed in claim 3, wherein the fragment comprises at least 10 nucleotides.
5. A construct as claimed in claim 3, wherein the fragment comprises at least 20 nucleotides.
6. A construct as claimed in claim 3, wherein the fragment comprises at least 30 nucleotides.
7. A construct as claimed in claim 3, wherein the fragment comprises at least 40 nucleotides.
8. A construct as claimed in claim 3, wherein the fragment comprises at least 50 nucleotides.
9. A construct as claimed in any one of claims 3 to 8, which is a vector, such as a plasmid, cosmid or phage.
10. A process for the preparation of DNA as claimed in claim 1 or 2 or a genetic construct in accordance with claim 3, the process comprising coupling successive nucleotides and/or ligating appropriate oligomers.
11. DNA substantially as herein described with reference to figure 2a.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8818775A GB2223496B (en) | 1988-08-08 | 1988-08-08 | Synthetic gene encoding mature human acid fibroblast growth factor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8818775A GB2223496B (en) | 1988-08-08 | 1988-08-08 | Synthetic gene encoding mature human acid fibroblast growth factor |
Publications (3)
Publication Number | Publication Date |
---|---|
GB8818775D0 GB8818775D0 (en) | 1988-09-07 |
GB2223496A true GB2223496A (en) | 1990-04-11 |
GB2223496B GB2223496B (en) | 1992-05-27 |
Family
ID=10641763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8818775A Expired - Fee Related GB2223496B (en) | 1988-08-08 | 1988-08-08 | Synthetic gene encoding mature human acid fibroblast growth factor |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2223496B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1309604A2 (en) * | 2000-08-15 | 2003-05-14 | Phage Biotechnology Corporation | Phage-dependent superproduction of biologically active protein and peptides |
JP2004517607A (en) * | 2000-08-15 | 2004-06-17 | ファージ バイオテクノロジー コーポレイション | Method of producing biologically active human acid fibroblast growth factor and its use in promoting angiogenesis |
EP3619324A4 (en) * | 2017-05-05 | 2020-12-30 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983004053A1 (en) * | 1982-05-06 | 1983-11-24 | Applied Molecular Genetics, Inc. | The manufacture and expression of large structural genes |
WO1987001728A1 (en) * | 1985-09-12 | 1987-03-26 | Biotechnology Research Partners, Ltd. | Recombinant fibroblast growth factors |
WO1987005332A1 (en) * | 1986-03-03 | 1987-09-11 | Meloy Laboratories Inc. | Recombinant human endothelial cell growth factor |
EP0298723A1 (en) * | 1987-07-07 | 1989-01-11 | California Biotechnology, Inc. | Recombinant fibroblast growth factors |
-
1988
- 1988-08-08 GB GB8818775A patent/GB2223496B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1983004053A1 (en) * | 1982-05-06 | 1983-11-24 | Applied Molecular Genetics, Inc. | The manufacture and expression of large structural genes |
WO1987001728A1 (en) * | 1985-09-12 | 1987-03-26 | Biotechnology Research Partners, Ltd. | Recombinant fibroblast growth factors |
WO1987005332A1 (en) * | 1986-03-03 | 1987-09-11 | Meloy Laboratories Inc. | Recombinant human endothelial cell growth factor |
EP0298723A1 (en) * | 1987-07-07 | 1989-01-11 | California Biotechnology, Inc. | Recombinant fibroblast growth factors |
Non-Patent Citations (1)
Title |
---|
Science 1986, 233 (4763), 541-545 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1309604A2 (en) * | 2000-08-15 | 2003-05-14 | Phage Biotechnology Corporation | Phage-dependent superproduction of biologically active protein and peptides |
JP2004517607A (en) * | 2000-08-15 | 2004-06-17 | ファージ バイオテクノロジー コーポレイション | Method of producing biologically active human acid fibroblast growth factor and its use in promoting angiogenesis |
JP2004528005A (en) * | 2000-08-15 | 2004-09-16 | ファージ バイオテクノロジー コーポレイション | Phage-dependent hyperproduction of biologically active proteins and peptides |
EP1309604A4 (en) * | 2000-08-15 | 2006-10-11 | Phage Biotechnology Corp | Phage-dependent superproduction of biologically active protein and peptides |
KR100761486B1 (en) * | 2000-08-15 | 2007-10-04 | 카디오배스큘러 바이오 떼러퓨틱스, 인크. | Phage-Dependent Superproduction of Biologically Active Protein and Peptides |
EP3619324A4 (en) * | 2017-05-05 | 2020-12-30 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
US11479591B2 (en) | 2017-05-05 | 2022-10-25 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Also Published As
Publication number | Publication date |
---|---|
GB2223496B (en) | 1992-05-27 |
GB8818775D0 (en) | 1988-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gunsalus et al. | Nucleotide sequence and expression of Escherichia coli trpR, the structural gene for the trp aporepressor. | |
CA1341124C (en) | Genetic engineering process for the preparation of hirudins, and means for carrying out this process | |
Williams et al. | Design, synthesis and expression of a human interteukin-2 gene incorporating the codon usage bias found in highly expressed Escherichia coli genes | |
Firtel et al. | Unusual nucleotide sequences at the 5'end of actin genes in Dictyostelium discoideum. | |
Kano et al. | Molecular cloning and nucleotide sequence of the HU-1 gene of Escherichia coli | |
Singer-Sam et al. | Isolation of a cDNA clone for human X-linked 3-phosphoglycerate kinase by use of a mixture of synthetic oligodeoxyribonucleotides as a detection probe. | |
Köster et al. | Iron hydroxamate transport of Escherichia coli: nucleotide sequence of the fhuB gene and identification of the protein | |
CA1339892C (en) | Preparation of polypeptides having human gamma enterferon activity | |
WO1989003422A1 (en) | Synthetic gene | |
DK166681B1 (en) | DNA SEQUENCES, DNA SEQUENCES AND DNA OLIGONUCLEOTIDES FOR USE IN THE PREPARATION OF THE FIRST DNA SEQUENCES, HYBRID PLASMIDS CONTAINING DNA SEQUENCE, HOUSE CELLS WITH 2 | |
WO1989003424A1 (en) | Synthetic gene | |
AU634926B2 (en) | Gene synthesis | |
White et al. | Evidence for a multigene family involved in bile acid 7-dehydroxylation in Eubacterium sp. strain VPI 12708 | |
GB2223496A (en) | Gene encoding human acidic fibroblast growth factor | |
JPS63304987A (en) | Gene engineering production of angiogenins | |
GB2213821A (en) | Synthetic gene | |
GB2223495A (en) | Gene encoding human basic fibroblast growth factor | |
GB2210883A (en) | Synthetic gene | |
GB2223497A (en) | Gene encoding human beta-endothelial cell growth factor | |
GB2217326A (en) | Synthetic gene encoding tumour necrosis factor beta | |
WO1989003423A1 (en) | Synthetic dna sequence coding for human insulin-like growth factor ii | |
GB2218420A (en) | Synthetic gene encoding interleukin-4 | |
EP0182383A1 (en) | Process for the preparation of oligo- and polydeoxyribonucleotides | |
GB2217325A (en) | Synthetic gene encoding tumour necrosis factor alpha | |
GB2217327A (en) | Synthetic gene encoding interleukin-6 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19930808 |